NOVARTIS AG (NVSEF) Financials
NVSEF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 99.9 billion | 53.2 billion |
| 2023-09-30 | 112.7 billion | 74.5 billion |
| 2023-06-30 | 111.0 billion | 59.0 billion |
| 2023-03-31 | 112.2 billion | 60.1 billion |
NVSEF Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 1.8 billion | 248.0 million |
| 2023-09-30 | 4.7 billion | 205.0 million |
| 2023-06-30 | 2.6 billion | 233.0 million |
| 2023-03-31 | 2.5 billion | 199.0 million |
NVSEF Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 2.6 billion |
| 2023-09-30 | 1.5 billion |
| 2023-06-30 | 2.3 billion |
| 2023-03-31 | 2.3 billion |
NVSEF Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 14.0 billion | - | 1.8 billion |
| 2023-09-30 | 12.7 billion | - | 1.7 billion |
| 2023-06-30 | 11.2 billion | - | 1.8 billion |
| 2023-03-31 | 12.3 billion | - | 1.8 billion |
NVSEF Shares Outstanding
NVSEF Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 783.0 million | 2.6 billion | 3.4 billion | - |
| 2023-09-30 | 683.0 million | 3.9 billion | 3.1 billion | - |
| 2023-06-30 | 996.0 million | 2.5 billion | 3.7 billion | - |
| 2023-03-31 | 470.0 million | 2.8 billion | 3.4 billion | - |
NVSEF Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 11.8 billion | 3.0 billion |
| 2023-09-30 | 12.1 billion | 3.1 billion |
| 2023-06-30 | 13.9 billion | 4.3 billion |
| 2023-03-31 | 13.2 billion | 3.9 billion |
NVSEF
Price: $102.14
Dividend Yield: 0.04%
Forward Dividend Yield: 3.77%
Payout Ratio: 93.80%
Dividend Per Share: 3.85 USD
Earnings Per Share: 4.10 USD
P/E Ratio: 24.57
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - General
Market Capitalization: 199.7 billion
Average Dividend Frequency: 1
Years Paying Dividends: 23
DGR3: 3.29%
DGR5: 2.52%
DGR10: 3.66%
DGR20: 7.13%